Promentis Pharmaceuticals: Promentis Pharmaceuticals commences phase 2 studies for SXC2023 targeting novel Glutamatergic mechanism

Promentis is developing SXC2023 along with other compounds that engage System xc a central nervous system target addressing glutamatergic imbalance and oxidative stress to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase ...